Table 2.
Clinicopathological features related to the ACRG subtypes.
| Variable | N (%) | MSI∗ (n = 13) | MSS/EMT (n = 29) | MSS/p53- (n = 33) | MSS/p53+ (n = 22) | P value |
|---|---|---|---|---|---|---|
| Gender | 0.917 | |||||
| -Male | 59 (60.8%) | 7 (53.8) | 17 (58.6) | 21 (63.6) | 14 (63.6) | |
| -Female | 38 (39.2%) | 6 (46.2) | 12 (41.4) | 12 (36.4) | 8 (36.4) | |
| Mean age at diagnosis (range) | 59 (28-85) | 59 (36-85) | 55 (28-76) | 60 (39-80) | 64 (39-82) | 0.101 |
| Age at diagnosis | 0.245 | |||||
| -≥50 years | 80 (82.5) | 9 (69.2) | 22 (75.9) | 29 (87.9) | 20 (90.9) | |
| -<50 years | 17 (17.5) | 4 (30.8) | 7 (24.1) | 4 (12.1) | 2 (9.1) | |
| History of gastrectomy | 0.023 | |||||
| -Yes | 7 (7.2) | 0 (0) | 4 (13.8) | 0 (0) | 3 (13.6) | |
| -No | 90 (92.8) | 13 (100) | 25 (86.2) | 33 (100) | 19 (86.4) | |
| History of gastric ulcer | 0.222 | |||||
| -Yes | 3 (3.1) | 0 (0) | 0 (0) | 1 (3) | 2 (9.1) | |
| -No | 94 (96.9) | 13 (100) | 29 (100) | 32 (97) | 20 (90.9) | |
| Tobacco smoking | 0.207 | |||||
| -Yes | 25 (25.8) | 1 (7.7) | 6 (20.7) | 11 (33.3) | 7 (31.8) | |
| -No | 72 (74.2) | 12 (92.3) | 23 (79.3) | 22 (66.7) | 15 (68.2) | |
| Tumor location | 0.156 | |||||
| -Cardia | 31 (31.9) | 4 (30.8) | 11 (37.9) | 13 (39.4) | 3 (13.6) | |
| -Noncardia | 66 (68.1) | 9 (69.2) | 18 (62.1) | 20 (60.6) | 19 (86.4) | |
| Tumor cells differentiation | 0.079 | |||||
| -Well/moderate | 62 (63.9) | 7 (53.8) | 16 (55.2) | 27 (81.8) | 12 (54.5) | |
| -Poor | 35 (36.1) | 6 (46.2) | 13 (44.8) | 6 (18.2) | 10 (45.5) | |
| Lauren classification | 0.003 | |||||
| -Intestinal | 65 (67.1) | 11 (84.6) | 12 (41.4) | 27 (81.8) | 15 (68.2) | |
| -Diffuse/mixed | 32 (32.9) | 2 (15.4) | 17 (58.6) | 6 (18.2) | 7 (31.8) | |
| HER2 immunostaining | 0.874 | |||||
| -Positive | 9 (9.3) | 1 (7.7) | 2 (6.9) | 3 (9.1) | 3 (13.6) | |
| -Negative | 88 (90.7) | 12 (92.3) | 27 (93.1) | 30 (90.9) | 19 (86.4) | |
| EBV | 0.296 | |||||
| -Positive | 6 (6.2) | 0 (0) | 1 (3.4) | 2 (6.1) | 3 (13.6) | |
| -Negative | 91 (93.8) | 13 (100) | 28 (96.6) | 31 (93.9) | 19 (86.4) | |
| PD-L1 immunostaining | n = 38 | n = 6 | n = 11 | n = 11 | n = 10 | 0.418 |
| -Positive | 6 (15.8) | 3 (50) | 1 (9.1) | 1 (9.1) | 1 (10) | |
| -Negative | 32 (84.2) | 3 (50) | 10 (90.9) | 10 (90.9) | 9 (90) |
MSI: microsatellite instability; MSS/EMT: microsatellite stable with epithelial-to-mesenchymal transition; MSS/p53-: microsatellite stable with inactive p53; MSS/p53+: microsatellite stable with active p53; ∗previously reported [13].